Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma Orphan Drug 2017 Report

Worldwide orphan drug sales forecast to total $209bn

EvaluatePharma Orphan Drug 2017 Report EvaluatePharma Orphan Drug 2017 Report EvaluatePharma Orphan Drug 2017 Report

Download Report

The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017.

What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.

Key highlights:

  • Worldwide orphan drug sales forecast to total $209bn (CAGR 2017 to 2022:+11.1%); approximately double overall prescription market growth
  • Orphan drugs set to be 21.4% of worldwide prescription sales by 2022 (excluding generics)
  • Median cost per patient differential 5.5 times higher for orphan drugs compared to non-orphan

              EvaluatePharma Orphan Drug 2017 Infographic

View Orphan Drug 2017 Infographic

Press Release


Confirm your details on form below to download this report